
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


SIGA Technologies Inc (SIGA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SIGA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit -23.04% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 461.51M USD | Price to earnings Ratio 9.64 | 1Y Target Price 17.53 |
Price to earnings Ratio 9.64 | 1Y Target Price 17.53 | ||
Volume (30-day avg) - | Beta 0.95 | 52 Weeks Range 4.48 - 11.62 | Updated Date 06/29/2025 |
52 Weeks Range 4.48 - 11.62 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.67 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 40.33% | Operating Margin (TTM) -32.03% |
Management Effectiveness
Return on Assets (TTM) 14.4% | Return on Equity (TTM) 25.47% |
Valuation
Trailing PE 9.64 | Forward PE 9.81 | Enterprise Value 300868611 | Price to Sales(TTM) 3.84 |
Enterprise Value 300868611 | Price to Sales(TTM) 3.84 | ||
Enterprise Value to Revenue 2.5 | Enterprise Value to EBITDA 5.28 | Shares Outstanding 71441104 | Shares Floating 40427794 |
Shares Outstanding 71441104 | Shares Floating 40427794 | ||
Percent Insiders 43.29 | Percent Institutions 51.72 |
Upturn AI SWOT
SIGA Technologies Inc

Company Overview
History and Background
SIGA Technologies Inc. was founded in 1995. It focuses on developing and commercializing solutions for life-threatening infectious diseases and bioweapons, with a primary focus on smallpox.
Core Business Areas
- Pharmaceuticals: Development, production, and commercialization of pharmaceutical products, primarily focused on antiviral drugs.
Leadership and Structure
Dr. Phillip L. Gomez is the Chief Executive Officer. The company has a typical corporate structure with departments overseeing R&D, manufacturing, sales, and administration.
Top Products and Market Share
Key Offerings
- Tpoxx (Tecovirimat): Tpoxx is an oral antiviral drug for the treatment of human smallpox disease. SIGA is the sole provider of a small molecule drug to treat smallpox, making it a unique offering with a solid market share. No other drugs are currently approved for smallpox treatment. Competitors include companies offering preventative vaccines such as Emergent Biosolutions (EBS).
Market Dynamics
Industry Overview
The industry focuses on biodefense and countermeasures against infectious diseases. Government contracts are a significant driver of revenue.
Positioning
SIGA is a key player in the biodefense market, holding a dominant position with Tpoxx. Competitive advantage lies in its sole-source contract for a small molecule drug for smallpox treatment.
Total Addressable Market (TAM)
The TAM includes government spending on biodefense and stockpiling programs. The global market is projected to be worth over $10 billion. SIGA is well-positioned to capture a significant portion of this market, particularly in the U.S.
Upturn SWOT Analysis
Strengths
- Sole provider of Tpoxx
- Strong government relationships
- Significant government contracts
- Experienced management team
Weaknesses
- Reliance on a single product
- Dependence on government funding
- Potential for generic competition (though protected by patents)
- Volatility in government spending
Opportunities
- Expansion into other antiviral markets
- Increased government funding for biodefense
- Partnerships with other pharmaceutical companies
- Geographic expansion of Tpoxx sales
Threats
- Changes in government policy
- Emergence of new infectious diseases
- Patent challenges
- Competition from other biodefense companies
Competitors and Market Share
Key Competitors
- EBS
- CMRX
Competitive Landscape
SIGA holds a dominant position due to Tpoxx. Competitors focus on vaccines and other biodefense solutions. SIGA's advantage is its sole-source drug for smallpox.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by government contracts for Tpoxx. The company has seen significant revenue increases in recent years.
Future Projections: Future growth is expected to be driven by continued government stockpiling and potential expansion into new markets and indications.
Recent Initiatives: Recent initiatives include securing new government contracts and exploring potential new applications for Tpoxx.
Summary
SIGA Technologies is a strong company with a unique position in the biodefense market due to its sole-source contract for Tpoxx. Its dependence on government funding is a risk, but continued government support for biodefense programs bodes well. The company should look to expand into other antiviral markets to diversify its revenue stream. Patent challenges and changes in government policy are ongoing threats.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations
- Market Research Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Investment decisions should be made based on your own due diligence and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About SIGA Technologies Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 1997-09-09 | CEO & Director Dr. Diem Nguyen M.B.A., Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 46 | Website https://www.siga.com |
Full time employees 46 | Website https://www.siga.com |
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. Its lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.